Is IRD a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The presbyopia decision due October 17, 2026, with revenue (ttm) at ~$9.9M, almost entirely Viatris collaboration reimbursement. The bear case rests on the trailing numbers do not support the valuation on any conventional measure, so essentially all of the market capitalization rests on events that have not happened yet. Analysts covering it are spread from $8.00 to $20.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The trailing numbers do not support the valuation on any conventional measure, so essentially all of the market capitalization rests on events that have not happened yet. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $8.00, +108.3% from the $3.84 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The presbyopia decision due October 17, 2026. Phentolamine ophthalmic solution 0.75% is already approved as RYZUMVI for a narrow diagnostic use, and Opus has an sNDA under review to extend it to presbyopia, the age-related loss of near vision that affects a very large share of adults over 45. The most optimistic analyst target on IRD is $20.00, +420.8% from the $3.84 price. That figure is only reachable if this thesis works close to its best case.

The trailing numbers do not support the valuation on any conventional measure, so essentially all of the market capitalization rests on events that have not happened yet. The BEST1 data that moved the stock more than 50 percent in September 2026 (a gain it largely gave back, falling about 25% in the following month) came from five patients in an open-label, uncontrolled cohort, and single-arm improvements in small numbers of retinal patients have historically failed to replicate in randomized trials. Revenue is falling rather than growing, because it is Viatris reimbursing development costs rather than product sales, and the phentolamine franchise is commercially controlled by Viatris, so Opus captures only royalties and milestones from whatever the drug becomes. The October 17, 2026 PDUFA date is a genuine binary: a complete response letter would remove the nearest source of non-dilutive cash. Inherited retinal disease markets are also very small in patient count and expensive to serve, AAV gene therapy carries a long industry history of manufacturing and immune-response setbacks, and the Oberland facility is debt-like capital whose obligations sit ahead of shareholders. The most pessimistic published target is $8.00, +108.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

A clinical stage ophthalmology company developing AAV gene therapies for inherited retinal diseases, alongside RYZUMVI, an FDA approved eye drop marketed by Viatris.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The presbyopia decision due October 17, 2026) stalling in the reported numbers rather than in the narrative, the risk above (the trailing numbers do not support the valuation on any conventional measure, so essentially all of the market capitalization rests on events that have not happened yet) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

IRD is Opus Genetics, Inc., listed on the Nasdaq Capital Market and headquartered in Durham, North Carolina. The ticker is a reference to inherited retinal disease, the company's main therapeutic focus. It files with the SEC under CIK 0001228627, a filer history that runs back through Ocuphire Pharma and Rexahn Pharmaceuticals, since the current company was formed when Ocuphire acquired the private Opus Genetics in late 2024 and adopted its name.

Yes, though indirectly. Phentolamine ophthalmic solution 0.75% is FDA-approved and sold as RYZUMVI for reversing pharmacologically-induced pupil dilation after an eye exam. Viatris holds exclusive US commercial rights under a licensing agreement, so Opus receives royalties and milestones rather than booking product sales. Everything else in the company's pipeline, including all of the gene therapy programs, remains investigational.

Trailing revenue of roughly $9.9 million is almost entirely Viatris reimbursing Opus for research and development services under their license agreement, plus a small amount of RYZUMVI royalty. It is a cost recovery line, not a commercial ramp, and it declines as programs finish, which is why first-half 2026 revenue of about $2.9 million was down from about $7.3 million a year earlier. Clinical-stage biotech valuations are set by pipeline expectations rather than by current revenue.